Dividends Inside 
Gyre Therapeutics, Inc.
GYRE
$6.01 (+ $0.07 + 1.18%)
Last updated: 2026-07-24 12:57 UTC
Gyre Therapeutics, Inc. trades under ticker GYRE on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US4037831033, CUSIP 403783103. Also searched as Gyre Therapeutics.
Related researchGYRE stock priceGYRE share priceGYRE dividend historyGYRE dividend yieldGyre Therapeutics dividend historyGyre Therapeutics dividend yield403783103Gyre Therapeutics stockGyre Therapeutics share price
About the Company
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.